問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 251New Taipei CityDanshuei

Recruiting Trial

41Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

291Cases

2011-05-01 - 2013-04-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-04-01 - 2017-03-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-10-01 - 2010-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-03-01 - 2017-05-31

Phase III

An Asian, Phase III, multicenter, randomized, double-blind, placebo-controlled, 14-week trial to evaluate the efficacy of DS-5565 in patients with diabetic peripheral neuropathy pain (DPNP), followed by a 52-week open period Mark the extension test.

  • Condition/Disease

    Diabetic peripheral neuropathy pain

  • Test Drug

    DS-5565

Participate Sites
17Sites

Terminated17Sites

2015-03-01 - 2017-05-31

Phase III

AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH POST-HERPETIC NEURALGIA FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION

  • Condition/Disease

    POST-HERPETIC NEURALGIA

  • Test Drug

    DS-5565

Participate Sites
14Sites

Terminated14Sites

2016-08-31 - 2018-12-31

Phase III

A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy versus Irinotecan Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Test Drug

    DE-766 injection 50 mg/10mL vial

Participate Sites
11Sites

Terminated10Sites

趙毅
Taipei Veterans General Hospital

2016-05-01 - 2018-12-31

Phase II

A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus (RSV) Infection

  • Test Drug

    AK0529

Participate Sites
4Sites

Terminated4Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack

  • Test Drug

    AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

2006-11-20 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2006-02-01 - 2007-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 24 25 26 27 28 30
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB